Jia Y, Yang Y, Zhan Q, et al. Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer [J]. J Mol Diagn, 2012, 14 (6): 577-585.
[2]
Toh Y, Egashira A, Yamamoto M. Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma [J]. Gen Thorac Cardiovasc Surg, 2013, 61 (5): 262-269.
[3]
Jemal A, Bray F, Center M M, et al. Global cancer statistics [J]. CA Cancer J Clin,2011, 61(2): 69-90.
[4]
Kaz A M, Grady W M. Epigenetic biomarkers in esophageal cancer [J]. Cancer, 2014, 342 (2): 193-199.
[5]
Zhang X M, Guo M Z. The value of epigenetic markers in esophageal cancer [J]. Fronti Med China, 2010, 4 (4): 378-384.
[6]
Chen X Y, He Q Y, Guo M Z. XAF1 is frequently methylated in human esophageal cancer [J]. World J Gastroenterol , 2012, 18 (22): 2844-2849.
[7]
Jia Y, Yang Y, Brock M V, et al. Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer [J]. J Pathol, 2013,230(2):194-204.
[8]
Jia Y, Yang Y S , Brock M V, et al. Methylation of TFPI-2 is an early event of esophageal carcinogenesis [J]. Epigenomics, 2012, 4(2): 135-146.
[9]
Herman J G, Graff J R, Myohanen S, et al. Methylation-specific PCR A novel PCR assay for methylation [J]. Proc Natl Acad Sci, 1996, 93: 9821-9826.
[10]
Rodriguez P M, Esteller M. Cancer epigenetics reaches mainstream oncology [J]. Nat Med, 2011, 17 (3): 330-339.
[11]
Xicola R M, Llor X. DNA methylation defects in sporadic and hereditary colorectal cancer [J]. Gastroenterol Hepatol, 2012, 35 (7): 480-487.
[12]
Li J S, Ying J M, Wang X W, et al. Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma [J]. Chin J Cancer, 2013, 32 (1): 3-11.
[13]
Agarwal A, Polineni R, Hussein Z, et al. Role of epigenetic alterations in the pathogenesis of Barrett’s esophagus and esophageal adenocarcinoma [J]. Int J Clinl Exp Pathol, 2012, 5 (5): 382-396.
[14]
Yousef F, Cardwell C, Cantwell M M, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus: a systematic review and meta-analysis [J]. Am J Epidemiol, 2008, 168 (3): 237-249.
[15]
Eads C A, Lord R V, Wickramasinghe K, et al. Epigenetic Patterns in the progression of esophageal adenocarcinoma[J]. Cancer Res, 2001, 61(8): 3410-3418.
[16]
Kazuyuki K, Brabender J, Lord R V, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma [J]. J Nati Cancer Inst, 2000, 92 (22): 1805-1811.
[17]
Shah A K, Saunders N A, Barbour A P, et al. Early diagnostic biomarkers for esophageal adenocarcinoma--the current state of play [J]. Cancer Epidemiol Biomarkers Prev, 2013, 22 (7): 1185-1209.
[18]
Guo M Z, Ren J, Brock M V, et al. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer [J]. Epigenetics, 2008, 3 (6): 336-341.
[19]
Li X, Zhou F, Jiang C, et al. Identification of a DNA methylome profile of esophageal squamous cell carcinoma and potential plasma epigenetic biomarkers for early diagnosis [J]. PloS One, 2014, 9 (7): e103-162.
[20]
Issa J P, Kantarjian H M, Kirkpatrick P. Azacitidine [J]. Nature reviews Drug discovery, 2005, 4 (4): 275-276.
Sakakura C, Miyagawa K, Fukuda K I, et al. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis [J]. Oncogene, 2007, 26 (40): 5927-5938.
[23]
Brock M V, Gou M, Akiyama Y, et al. Prognostic Importance of Promoter Hypermethylation of Multiple genes in esophageal adenocarcinoma[J]. Clin Cancer Res, 2003, 9(8): 2912-2919.
[24]
Lee E, Lee B B, Ko E, et al. Cohypermethylation of p14 in combination with CADM1 or DCC as a recurrence-related prognostic indicator in stage I esophageal squamous cell carcinoma [J]. Cancer,2013, 119 (9): 1752-1760.
2016, Vol. 27 
